Ironwood Pharmaceuticals, Inc.
IRWD
$0.5662
-$0.0282-4.74%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -23.18% | -20.63% | -12.48% | -6.25% | -0.86% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -23.18% | -20.63% | -12.48% | -6.25% | -0.86% |
| Cost of Revenue | -52.03% | 22.84% | -64.71% | -45.57% | -58.70% |
| Gross Profit | -21.79% | -21.24% | -1.37% | -0.49% | 6.36% |
| SG&A Expenses | -12.10% | 1.31% | 27.39% | 28.21% | 25.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.52% | 3.44% | 41.83% | 61.68% | 61.82% |
| Operating Income | -49.69% | -50.94% | -58.92% | -53.07% | -41.69% |
| Income Before Tax | 102.38% | 106.88% | 107.90% | 109.92% | -485.37% |
| Income Tax Expenses | -22.29% | -22.96% | -0.13% | 3.34% | -9.24% |
| Earnings from Continuing Operations | 97.01% | 100.09% | 99.68% | 100.76% | -694.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -97.70% | -92.57% | -- |
| Net Income | 96.93% | 100.09% | 99.74% | 101.00% | -678.16% |
| EBIT | -49.69% | -50.94% | -58.92% | -53.07% | -41.69% |
| EBITDA | -48.97% | -50.32% | -58.29% | -52.66% | -41.29% |
| EPS Basic | 97.04% | 100.08% | 99.74% | 101.01% | -671.31% |
| Normalized Basic EPS | -75.42% | -72.32% | -76.44% | -70.45% | -32.29% |
| EPS Diluted | 97.00% | 99.98% | 99.62% | 100.74% | -774.49% |
| Normalized Diluted EPS | -74.44% | -70.04% | -73.61% | -69.17% | -21.49% |
| Average Basic Shares Outstanding | 2.27% | 2.28% | 2.16% | 2.01% | 1.76% |
| Average Diluted Shares Outstanding | -2.49% | -7.09% | -11.37% | -7.32% | -11.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |